Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
May 24 2022 - 8:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced acceptance of its abstract titled, “TAM Targeted Imaging
Agents Binding CD206 and Selective Blocking of Off Target Liver
Localization” for presentation at this year’s Society of Nuclear
Medicine and Molecular Imaging (“SNMMI”) Annual Meeting. This work
was performed as part of an ongoing research collaboration with the
University of Alabama at Birmingham (“UAB”), in the laboratory of
Dr. Suzanne Lapi, Professor and Vice Chair of Research in the UAB
Department of Radiology. The poster will be presented by Dr.
Jennifer Bartels of UAB.
This year’s annual SNMMI meeting will be held June 11-14 in
Vancouver, British Columbia, Canada. The presentation will take
place Saturday, June 11, from 6 pm – 8 pm PDT (abstract ID 197;
program ID 2862). The abstract will be accessible on the SNMMI’s
Annual Meeting website prior to the meeting
(https://am.snmmi.org/iMIS/SNMMI-AM).
The objectives of this preclinical study were to evaluate tumor
localization of two new CD206 targeted mannosylated dextran
(Navidea’s Manocept platform) imaging agents as well as an approach
to reduce uptake of these imaging agents by the liver. The new
imaging agents were labeled with gallium-68 (“68Ga”) to enable
positron emission tomography (“PET”) imaging. The ultimate goals
are to develop next generation Manocept imaging agents that offer
improved on-target localization and reduced off-target
localization. CD206 is a receptor expressed primarily on activated
macrophages, including tumor associated macrophages (“TAMs”), as
well as the Kupffer cells of the liver. TAM-targeted Manocept
imaging enables imaging of tumors. The information gained from
these experiments also suggests strategies to improve targeted
delivery of therapeutic payloads to TAMs and other clinically
significant targets, while simultaneously reducing off-target liver
toxicity.
The experiments described in the poster evaluated the
biodistribution in mice with and without tumors of the new
68Ga-labeled Manocept imaging agents that differed in their
molecular weights. Also evaluated were the effects on their
biodistributions of prior administration of unlabeled constructs or
a construct designed to specifically block off-target liver
localization. Results showed that the amount of the two imaging
agents that localized to tumors differed significantly. Also,
pretreatment with the construct designed to selectively block liver
localization did significantly reduced liver localization of the
68Ga-labeled imaging agents without reducing their localizations to
tumors.
Dr. Suzanne Lapi said, “My research group and I are pleased to
present this collaborative work with Navidea at SNMMI and to
continue to further advance this project with possible far reaching
medical imaging and commercial potentials.”
Dr. Michael Rosol, Chief Medical Officer for Navidea, said, “We
are delighted by the opportunity to present these results at this
internationally recognized meeting.” Dr. Rosol continued, “This is
another example in a line of research collaborations we have had
with the highest level of researchers at top tier institutions that
is resulting in work advancing our platform technology. These new
technologies suggest exciting new applications in medical imaging
and possibly also new therapeutic strategies.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
About UAB
Known for its innovative and interdisciplinary approach to
education at both the graduate and undergraduate levels, the
University of Alabama at Birmingham, a part of the University of
Alabama System, is an internationally renowned research university
and academic medical center with over $600 million in research
awards annually, as well as Alabama’s largest single employer, with
some 26,000 employees, and has an annual economic impact exceeding
$7.15 billion on the state. The pillars of UAB’s mission include
education, research, innovation and economic development, community
engagement, and patient care. Learn more at www.uab.edu.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and ability to obtain additional financing; our
ability to continue as a going concern; the final outcome of any
pending litigation; our ability to successfully complete research
and further development of our drug candidates; the timing, cost
and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; dependence on royalties and grant revenue; our ability
to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220524005401/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. Jeffrey Smith Vice President of Operations 614-822-2365
jsmith@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024